Literature DB >> 27875972

The Role of Chinese Herbal Medicines and Bioactive Ingredients Targeting Myocardial KCa and KATP Channels in Cardiovascular Diseases.

Yan Dong1, Pengqian Wang2, Xue Feng3, Bing Li2, Zhong Wang2, Haixia Li1.   

Abstract

Cardiovascular disorders are the most common diseases all over the world, which have limitations in the current treatment stratergies. As two subtypes of potassium channel, KCa and KATP ion channels are playing important roles in the occurrence and development of cardiovascular diseases. KCa by activating the signal pathway of c-Src/PI3-kinase/Akt-dependent or eNOS-NO-cGMP effects the function of vascular endothelial cell, while KATP acting as a medium combines the cell electrical activity and energy metabolism. Thus, through acting on KCa or/and KATP, some drugs can play roles in these cardiovascular diseases. Nevertheless, specific and effective western medicines selectively working on these two channels are not identified at present. Some Chinese herbal medicines or bioactive ingredients in contrast have been discovered to be safe and effective in the regulation of the two recently. Therefore, this review article summarized some single herbs and bioactive ingredients targeting KCa or/and KATP ion channels in the management of cardiovascular diseases, with the purpose of demonstrating the alternative treatment of these diseases in perspective of Traditional Chinese medicine. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Bioactive ingredients; KATP potassium channels; KCa; cardiovascular diseases; chinese herbal medicines

Mesh:

Substances:

Year:  2017        PMID: 27875972     DOI: 10.2174/1381612823666161122141755

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  1 in total

1.  Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro.

Authors:  Jinqiang Zhu; Wanshan Song; Shixin Xu; Yan Ma; Baoyu Wei; Hongwu Wang; Shengyu Hua
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.